Clinical Practice Guidelines on Biologics for Chronic Rhinosinusitis แนวทางเวชปฏิบัติการใช้ยากลุ่มชีววัตถุ (Biologics) ในโรคไซนัสอักเสบเรื้อรัง (ฉบับ พ.ศ. 2566)
Article Sidebar
Main Article Content
Abstract
บทคัดย่อ (Abstract)
โรคไซนัสอักเสบเรื้อรังเป็นโรคที่พบบ่อย และรบกวนต่อคุณภาพชีวิตของผู้ป่วย การรักษาประกอบด้วย
การรักษาด้วยยา และการผ่าตัด ในผู้ป่วยบางรายอาจมีภาวะไซนัสอักเสบที่ไม่ตอบสนองต่อการรักษา
(Recalcitrant sinusitis) ถึงแม้จะได้รับการรักษาที่เหมาะสมตามมาตรฐานแล้ว
จากการค้นคว้าวิจัยในปัจจุบันถึง กลไกในการก่อโรค และแนวทางการรักษา
ได้มีการรักษามุ่งเป้าด้วยยาชีววัตถุ (Biologics) ในผู้ป่วยไซนัสอักเสบ เรื้อรังประเภทที่ 2 (Type 2
Chronic rhinosinusitis) เช่น anti-IgE, anti-IL5, anti-IL5R, anti‐IL4R และ anti‐ IL13
อย่างไรก็ตามด้วยข้อจ ากัดเรื่องจ านวนของผู้ป่วยที่เป็นโรค การเข้าถึงของยา
และค่าใช้จ่ายที่เกิดขึ้นในการ รักษา ดังนั้นการศึกษาถึงข้อบ่งชี้ในการใช้ยา Biologics
และแนวทางติดตามผลการรักษาในบริบทของผู้ป่วยใน ประเทศไทยจึงเป็นสิ่งจ าเป็น สมาคมแพทย์โรคจมูก (ไทย)
ร่วมกับสมาคมโรคภูมิแพ้ โรคหืด และวิทยาภูมิคุ้มกัน แห่งประเทศไทย และราชวิทยาลัยโสต ศอ
นาสิกแพทย์แห่งประเทศไทย จึงได้จัดท าแนวทางเวชปฏิบัติการใช้ยา Biologics ในโรคไซนัสอักเสบเรื้อรัง
(ฉบับ พ.ศ. 2566) เพื่อเป็นแนวทางให้ โสต ศอ นาสิกแพทย์ กุมารแพทย์ แพทย์โรคภูมิแพ้
และแพทย์เฉพาะทางระบบทางเดินหายใจ ได้ใช้ประกอบการพิจารณาเลือกการรักษาด้วยยา
Biologics ในผู้ป่วยไซนัสอักเสบเรื้อรังได้อย่างถูกต้อง เหมาะสม และคุ้มค่า
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ต้นฉบับที่ส่งมาพิจารณายังวารสารหู คอ จมูก และใบหน้า จะต้องไม่อยู่ในการพิจารณาของวารสารอื่น ในขณะเดียวกันต้นฉบับที่จะส่งมาจะผ่านการอ่านโดยผู้ทรงคุณวุฒิ หากมีการวิจารณ์หรือแก้ไขจะส่งกลับไปให้ผู้เขียนตรวจสอบแก้ไขอีกครั้ง ต้นฉบับที่ผ่านการพิจารณาให้ลงตีพิมพ์ถือเป็นสมบัติของวารสารหู คอ จมูกและใบหน้า ไม่อาจนำไปลงตีพิมพ์ที่อื่นโดยไม่ได้รับอนุญาต
ตารางแผนภูมิ รูปภาพ หรือข้อความเกิน 100 คำที่คัดลอกมาจากบทความของผู้อื่น จะต้องมีใบยินยอมจากผู้เขียนหรือผู้ทรงลิขสิทธิ์นั้นๆ และใหร้ะบุกำกับไว้ในเนื้อเรื่องด้วย
References
เอกสารอ้างอิง
Fokkens, W.J., et al., European Position Paper on Rhinosinusitis and Nasal Polyps 2020.
Rhinology, 2020. 58(Suppl S29): p. 1-464.
Orlandi, R.R., et al., International consensus statement on allergy and rhinology:
rhinosinusitis 2021. Int Forum Allergy Rhinol, 2021. 11(3): p. 213-739.
Fokkens, W.J., et al., EUFOREA consensus on biologics for CRSwNP with or without asthma.
Allergy, 2019. 74(12): p. 2312-2319.
Xu, X., et al., Updates in biologic therapy for chronic rhinosinusitis with nasal polyps and
NSAID-exacerbated respiratory disease. Allergy, 2022. 77(12): p. 3593-3605.
Tai, J., M. Han, and T.H. Kim, Therapeutic Strategies of Biologics in Chronic Rhinosinusitis:
Current Options and Future Targets. Int J Mol Sci, 2022. 23(10).
Patel, G.B. and A.T. Peters, The Role of Biologics in Chronic Rhinosinusitis With Nasal
Polyps. Ear Nose Throat J, 2021. 100(1): p. 44-47.
Roland, L.T., et al., Guidance for contemporary use of biologics in management of chronic
rhinosinusitis with nasal polyps: discussion from a National Institutes of Health-sponsored
workshop. Int Forum Allergy Rhinol, 2020. 10(9): p. 1037-1042.
Hirsch, A.G., et al., Nasal and sinus symptoms and chronic rhinosinusitis in a population‐
based sample. Allergy, 2017. 72(2): p. 274-281.
Bhattacharyya, N. and S. Gilani, Prevalence of potential adult chronic rhinosinusitis symptoms
in the United States. Otolaryngology–Head and Neck Surgery, 2018. 159(3): p. 522-525.
Klossek, J.M., et al., Prevalence of nasal polyposis in France: a cross‐sectional, case–
control study. Allergy, 2005. 60(2): p. 233-237.
Yao, Y., M. Zeng, and Z. Liu, Revisiting Asian chronic rhinosinusitis in the era of type 2
biologics. Clinical & Experimental Allergy, 2022. 52(2): p. 231-243.
Chee, J., et al., Epidemiology and aetiology of chronic rhinosinusitis in Asia—A narrative
review. Clinical Otolaryngology, 2022.
Ahn, J.-C., et al., Prevalence and risk factors of chronic rhinosinusitus, allergic rhinitis,
and nasal septal deviation: results of the Korean National Health and Nutrition Survey 2008- 2012.
JAMA otolaryngology–head & neck surgery, 2016. 142(2): p. 162-167.
Wang, X.D., et al., An increased prevalence of self‐reported allergic rhinitis in major
Chinese cities from 2005 to 2011. Allergy, 2016. 71(8): p. 1170-1180.
Shi, J.B., et al., Epidemiology of chronic rhinosinusitis: results from a cross‐sectional
survey
in seven C hinese cities. Allergy, 2015. 70(5): p. 533-539.
Bachert, C., et al., Rhinosinusitis and asthma: a link for asthma severity. Current allergy
and asthma reports, 2010. 10: p. 194-201.
Bhan, N., et al., Time trends in racial and ethnic disparities in asthma prevalence in the
United States from the Behavioral Risk Factor Surveillance System (BRFSS) Study (1999– 2011).
American journal of public health, 2015. 105(6): p. 1269-1275.
Heffler, E., et al., The severe asthma network in Italy: findings and perspectives. The
journal of allergy and clinical immunology: In practice, 2019. 7(5): p. 1462-1468.
Thanaviratananich, S., et al., Burden of respiratory disease in Thailand: results from the
APBORD observational study. Medicine, 2016. 95(28).
Gliklich, R.E. and R. Metson, The health impact of chronic sinusitis in patients seeking
otolaryngologic care. Otolaryngology—Head and Neck Surgery, 1995. 113(1): p. 104-109.
Fu, C.H., et al., Nasal nitric oxide in relation to quality-of-life improvements after
endoscopic sinus surgery. Am J Rhinol Allergy, 2015. 29(6): p. e187-91.
Remenschneider, A.K., et al., EQ-5D-derived health utility values in patients undergoing
surgery for chronic rhinosinusitis. Laryngoscope, 2015. 125(5): p. 1056-61.
Schlosser, R.J., et al., Burden of illness: a systematic review of depression in chronic
rhinosinusitis. American Journal of Rhinology & Allergy, 2016. 30(4): p. 250-256.
Hopkins, C., et al., Psychometric validity of the 22-item Sinonasal Outcome Test. Clin
Otolaryngol, 2009. 34(5): p. 447-54.
Fuller, J.C., P.A. Levesque, and R.W. Lindsay, Assessment of the EuroQol 5-dimension
questionnaire for detection of clinically significant global health-related quality-of-life
improvement following functional septorhinoplasty. JAMA facial plastic surgery, 2017. 19(2): p.
-100.
Alt, J.A., et al., Sleep quality and disease severity in patients with chronic
rhinosinusitis.
The Laryngoscope, 2013. 123(10): p. 2364-2370.
Alt, J.A., et al., Sleep and quality of life improvements after endoscopic sinus surgery in
patients with chronic rhinosinusitis. Int Forum Allergy Rhinol, 2014. 4(9): p. 693-701.
Soler, Z.M., et al., Cognitive function in chronic rhinosinusitis: a controlled clinical
study.
Int Forum Allergy Rhinol, 2015. 5(11): p. 1010-7.
Caulley, L., et al., Direct costs of adult chronic rhinosinusitis by using 4 methods of
estimation: results of the US Medical Expenditure Panel Survey. Journal of Allergy and Clinical
Immunology, 2015. 136(6): p. 1517-1522.
Rudmik, L., Economics of chronic rhinosinusitis. Current allergy and asthma reports, 2017. 17:
p. 1-10.
Murphy, M.P., et al., Health care utilization and cost among adults with chronic
rhinosinusitis enrolled in a health maintenance organization. Otolaryngol Head Neck Surg, 2002.
(5): p. 367-76.
Bhattacharyya, N., et al., Cost burden and resource utilization in patients with chronic
rhinosinusitis and nasal polyps. Laryngoscope, 2019. 129(9): p. 1969-1975.
Goetzel, R.Z., et al., The health and productivity cost burden of the" top 10" physical and
mental health conditions affecting six large US employers in 1999. Journal of occupational and
environmental medicine, 2003: p. 5-14.
Stull, D.E., et al., Relationship of nasal congestion with sleep, mood, and productivity.
Current medical research and opinion, 2007. 23(4): p. 811-819.
Rudmik, L., et al., Productivity costs in patients with refractory chronic rhinosinusitis.
The Laryngoscope, 2014. 124(9): p. 2007-2012.
Thanaviratananich, S., et al., Burden of respiratory disease in Thailand: Results from the
APBORD observational study. Medicine (Baltimore), 2016. 95(28): p. e4090.
Scangas, G.A., et al., Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for
Chronic Rhinosinusitis With Nasal Polyps. Laryngoscope, 2021. 131(1): p. E26-E33.
ธนะวัฒน์ วงศ์ผัน, ก., และ กระทรวงสาธารณสุข, รายงานวิจัยเรื่องการศึกษาความคุ้มค่าทางเศรษฐศาสตร์
และข้อเสนอเพื่อปรับราคายา Omalizumab ที่เหมาะสมส าหรับผู้ป่วยหอบหืดในประเทศไทย กระทรวง สาธารณสุข,
กรมการค้าภายใน. ระบบค้นหาและเปรียบเทียบราคายา. 2023; Available f rom:
https://hospitals.dit.go.th/app/drug_price_search.php.
Fokkens, W., V. Lund, and J. Mullol, European position paper on rhinosinusitis and nasal
polyps 2007. Rhinol Suppl, 2007. 20: p. 1-136.
Fokkens, W.J., et al., European Position Paper on Rhinosinusitis and Nasal Polyps 2012.
Rhinol Suppl, 2012. 23: p. 3 p preceding table of contents, 1-298.
Tomassen, P., et al., Inflammatory endotypes of chronic rhinosinusitis based on cluster
analysis of biomarkers. J Allergy Clin Immunol, 2016. 137(5): p. 1449-1456.e4.
Akdis, C.A., et al., Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document
of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy,
Asthma & Immunology. J Allergy Clin Immunol, 2013. 131(6): p. 1479-90.
Annunziato, F., C. Romagnani, and S. Romagnani, The 3 major types of innate and adaptive
cell-mediated effector immunity. J Allergy Clin Immunol, 2015. 135(3): p. 626-35.
Khan, A., et al., The Global Allergy and Asthma European Network (GALEN rhinosinusitis
cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without
nasal polyps. Rhinology, 2019. 57(1): p. 32-42.
Zhang, Y., et al., Chronic rhinosinusitis in Asia. J Allergy Clin Immunol, 2017. 140(5): p.
- 1239.
Cao, P.P., et al., Distinct immunopathologic characteristics of various types of chronic
rhinosinusitis in adult Chinese. J Allergy Clin Immunol, 2009. 124(3): p. 478-84, 484.e1-2.
Bachert, C., et al., Nasal polyposis: from cytokines to growth. Am J Rhinol, 2000. 14(5): p.
-90.
Bachert, C., et al., Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin
Immunol, 2020. 145(3): p. 725-739.
Hu, J., et al., Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE
antibodies to eliminating IgE(+) B cells. Clin Transl Allergy, 2018. 8: p. 27.
Oettgen, H.C., Fifty years later: Emerging functions of IgE antibodies in host defense,
immune regulation, and allergic diseases. J Allergy Clin Immunol, 2016. 137(6): p. 1631- 1645.
Lawrence, M.G., et al., Half-life of IgE in serum and skin: Consequences for anti-IgE therapy
in patients with allergic disease. J Allergy Clin Immunol, 2017. 139(2): p. 422-428.e4.
McCoy, K.D., et al., Natural IgE production in the absence of MHC Class II cognate help.
Immunity, 2006. 24(3): p. 329-39.
Wright, J.D., et al., Structural and Physical Basis for Anti-IgE Therapy. Sci Rep, 2015. 5:
p. 11581.
Presta, L.G., et al., Humanization of an antibody directed against IgE. J Immunol, 1993.
(5): p. 2623-32.
MacGlashan, D.W., Jr., et al., Down-regulation of Fc(epsilon)RI expression on human basophils
during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol, 1997. 158(3): p.
-45.
Novosad, J. and I. Krčmová, Evolution of our view on the IgE molecule role in bronchial
asthma and the clinical effect of its modulation by omalizumab: Where do we stand today? Int J
Immunopathol Pharmacol, 2020. 34: p. 2058738420942386.
Chang, T.W., et al., Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.
Adv Immunol, 2007. 93: p. 63-119.
Navines-Ferrer, A., et al., IgE-Related Chronic Diseases and Anti-IgE-Based Treatments. J
Immunol Res, 2016. 2016: p. 8163803.
THAI JOURNAL OF OTOLA YNGOLOGY HEAD AND NECK SURGERY
Vol. 24 No. 2: Jul - Dec 202
Kariyawasam, H.H. and L.K. James, Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE
with Anti-IgE Omalizumab Therapy. Drug Des Devel Ther, 2020. 14: p. 5483-5494.
Schulman, E.S., Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for
the treatment of allergic respiratory disorders. Am J Respir Crit Care Med, 2001. 164(8 Pt 2): p.
S6-11.
Bachert, C., et al., Staphylococcus aureus and its IgE-inducing enterotoxins in asthma:
current knowledge. Eur Respir J, 2020. 55(4).
Zhang, N., et al., Mucosal tissue polyclonal IgE is functional in response to allergen and
SEB. Allergy, 2011. 66(1): p. 141-8.
Xolair [package insert]. 2019, Novatis Pharma AG: Switzerland.
Gevaert, P., et al., Long-term efficacy and safety of omalizumab for nasal polyposis in an
open-label extension study. J Allergy Clin Immunol, 2022. 149(3): p. 957-965.e3.
Damask, C., et al., Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and
POLYP 2 Subgroup Analysis. Am J Rhinol Allergy, 2022. 36(1): p. 135-141.
Wu, Q., et al., Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or
Mepolizumab? A Network Meta-Analysis. Int Arch Allergy Immunol, 2022. 183(3): p. 279- 288.
Oykhman, P., et al., Comparative efficacy and safety of monoclonal antibodies and aspirin
desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network
meta-analysis. J Allergy Clin Immunol, 2022. 149(4): p. 1286-1295.
Cai, S., et al., Comparison of Different Biologics for Treating Chronic Rhinosinusitis With
Nasal Polyps: A Network Analysis. J Allergy Clin Immunol Pract, 2022. 10(7): p. 1876- 1886.e7.
Wu, Q., et al., Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal
polyps: a systematic review and meta-analysis of randomised controlled trials. BMJ Open, 2021.
(9): p. e047344.
Peters, A.T., et al., Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis
with Nasal Polyps. J Allergy Clin Immunol Pract, 2021. 9(6): p. 2461-2471.e5.
Chong, L.Y., et al., Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev, 2021.
(3): p. Cd013513.
Rivero, A. and J. Liang, Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal
Polyposis: A Systematic Review and Meta-analysis. Ann Otol Rhinol Laryngol, 2017. 126(11): p.
-747.
Ashraf A. Wahba, A.M.A., Anti-immunoglobulin E therapy: is it a valid option for the
management of chronic rhinosinusitis with nasal polyposis? The Egyptian Journal of Otolaryngology,
35: p. 269-277.
NCT01066104. Subcutaneous omalizumab for treatment of chronic rhinosinusitis with nasal
polyposis. https://clinicaltrials.gov/show/nct010661042009 . CENTRAL. 2017.
EUCTR2017-001718-28-BE. A phase 3 clinical trial of omalizumab for chronic rhinosinusitis with
nasal polyps [A phase III, randomized, multicenter, double-blind, placebo-controlled clinical trial
of omalizumab in patients with chronic rhinosinusitis with nasal polyps].
https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001718-28/BE (first received 10
November 2017). [CENTRAL: CN-01908643] CENTRAL. 2017.
EUCTR2017-001724-22-PL. A phase 3 clinical trial of omalizumab for chronic rhinosinusitis with
nasal polyps [A phase III, randomized, multicenter, double-blind, placebo-controlled clinical trial
of omalizumab in patients with chronic rhinosinusitis with nasal polyps].
https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001724-22/GB (first received 6 November
. [CENTRAL: CN-01889769] CENTRAL. 2017.
Gevaert, P., et al., Omalizumab is effective in allergic and nonallergic patients with nasal
polyps and asthma. J Allergy Clin Immunol, 2013. 131(1): p. 110-6.e1.
Pinto, J.M., et al., A randomized, double-blind, placebo-controlled trial of anti-IgE for
chronic rhinosinusitis. Rhinology, 2010. 48(3): p. 318-24.
Gevaert, P., et al., Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase
trials. J Allergy Clin Immunol, 2020. 146(3): p. 595-605.
Corren, J., et al., Safety and tolerability of omalizumab. Clin Exp Allergy, 2009. 39(6): p.
-97.
Kawamatawong, T., et al., Long-term effectiveness of omalizumab treatment in Thai severe
asthmatic patients: A real-life experience. Asian Pac J Allergy Immunol, 2018. 36(4):
p. 238-243.
Kaplan, A., et al., Omalizumab in patients with symptomatic chronic idiopathic/spontaneous
urticaria despite standard combination therapy. J Allergy Clin Immunol, 2013. 132(1): p. 101-9.
Long, A., et al., Incidence of malignancy in patients with moderate-to-severe asthma treated
with or without omalizumab. J Allergy Clin Immunol, 2014. 134(3): p. 560-567.e4.
Busse, W., et al., Omalizumab and the risk of malignancy: results from a pooled analysis.
J Allergy Clin Immunol, 2012. 129(4): p. 983-9.e6.
Omalizumab [Thai package insert]. Approved version: Dec 2019.
THAI JOURNAL OF OTOLARYNGOLOGY HEAD AND NECK SURGERY
Vol. 24 No. 2: Jul - Dec 2023
Aarden LA, e.a., Revised nomenclature for antigen-nonspecific T cell proliferation and helper
factors. J Immunol, 1979. 123(6): p. 2928-9.
Lopez, A.F., et al., Murine eosinophil differentiation factor. An eosinophil-specific colony-
stimulating factor with activity for human cells. J Exp Med, 1986. 163(5): p. 1085-99.
FDA, : Nucala (mepolizumab) for subcutaneous injection.
Wang, Q., et al., Efficacy and Safety of Anti-Interleukin-5 Therapies in Chronic
Rhinosinusitis with Nasal Polyps: A Systematic Review and Meta-Analysis of Randomized Controlled
Trials. Int Arch Allergy Immunol, 2022. 183(7): p. 732-743.
Gevaert, P., et al., Nasal IL-5 levels determine the response to anti-IL-5 treatment in
patients with nasal polyps. J Allergy Clin Immunol, 2006. 118(5): p. 1133-41.
Gevaert, P., et al., Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe
nasal polyposis. J Allergy Clin Immunol, 2011. 128(5): p. 989-95.e1-8.
Bachert, C., et al., Reduced need for surgery in severe nasal polyposis with mepolizumab:
Randomized trial. J Allergy Clin Immunol, 2017. 140(4): p. 1024-1031 e14.
Han, J.K., et al., Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med, 2021. 9(10): p.
-1153.
Nasta, M.S., V.A. Chatzinakis, and C.C. Georgalas, Updates on current evidence for biologics
in chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg, 2020. 28(1): p. 18-24.
Desai, M., J. Oppenheimer, and D.M. Lang, Immunomodulators and Biologics: Beyond Stepped-Care
Therapy. Clin Chest Med, 2019. 40(1): p. 179-192.
Damask, C.C., et al., Targeted Molecular Therapies in Allergy and Rhinology. Otolaryngol Head
Neck Surg, 2021. 164(1_suppl): p. S1-S21.
Pelaia, C., et al., Benralizumab: From the Basic Mechanism of Action to the Potential Use in
the Biological Therapy of Severe Eosinophilic Asthma. Biomed Res Int, 2018. 2018: p. 4839230.
Agache, I., et al., Efficacy and safety of treatment with biologicals (benralizumab,
dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines
- recommendations on the use of biologicals in severe asthma. Allergy, 2020. 75(5): p. 1043-1057.
Al Efraij, K. and J.M. FitzGerald, Benralizumab for the add-on maintenance treatment of
patients with severe asthma aged 12 years and older with an eosinophilic phenotype.
xpert Rev Clin Pharmacol, 2018. 11(7): p. 669-676.
Cai, S., et al., Comparison of Different Biologics for Treating Chronic Rhinosinusitis With
Nasal Polyps: A Network Analysis. J Allergy Clin Immunol Pract, 2022. 10(7): p. 1876-1886 e7.
Tversky, J., A.P. Lane, and A. Azar, Benralizumab effect on severe chronic rhinosinusitis
with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial. Clin Exp Allergy,
51(6): p. 836-844.
Takabayashi, T., et al., A Phase II, Multicenter, Randomized, Placebo-Controlled Study of
Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic
Chronic Rhinosinusitis. Am J Rhinol Allergy, 2021. 35(6): p. 861-870.
Canonica, G.W., et al., Benralizumab improves symptoms of patients with severe, eosinophilic
asthma with a diagnosis of nasal polyposis. Allergy, 2022. 77(1): p. 150-161.
Bachert, C., et al., Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal
polyps: A randomized, placebo-controlled trial. J Allergy Clin Immunol, 2022. 149(4): p. 1309-1317
e12.
Lombardo, N., et al., Real-life effects of benralizumab on allergic chronic rhinosinusitis
and nasal polyposis associated with severe asthma. Int J Immunopathol Pharmacol, 2020. 34: p.
FitzGerald, J.M., et al., Benralizumab, an anti-interleukin-5 receptor alpha monoclonal
antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA):
a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 2016. 388(10056): p.
-2141.
Takabayashi, T. and R.P. Schleimer, Formation of nasal polyps: The roles of innate type 2
inflammation and deposition of fibrin. J Allergy Clin Immunol, 2020. 145(3): p. 740-750.
Schleimer, R.P., Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis. Annu Rev
Pathol, 2017. 12: p. 331-357.
Wynn, T.A., Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol, 2015.
(5): p. 271-82.
Gandhi, N.A., et al., Targeting key proximal drivers of type 2 inflammation in disease. Nat
Rev Drug Discov, 2016. 15(1): p. 35-50.
LaPorte, S.L., et al., Molecular and structural basis of cytokine receptor pleiotropy in the
interleukin-4/13 system. Cell, 2008. 132(2): p. 259-72.
Nelms, K., et al., The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev
Immunol, 1999. 17: p. 701-38.
Le Floc'h, A., et al., Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody,
is required to broadly inhibit type 2 inflammation. Allergy, 2020. 75(5): p. 1188-1204.
Barranco, P., et al., Dupilumab in the management of moderate-to-severe asthma: the data so
far. Ther Clin Risk Manag, 2017. 13: p. 1139-1149.
Klonowska, J., et al., New Cytokines in the Pathogenesis of Atopic Dermatitis-New Therapeutic
Targets. Int J Mol Sci, 2018. 19(10).
Strid, J., W.H.I. McLean, and A.D. Irvine, Too Much, Too Little or Just Enough: A Goldilocks
Effect for IL-13 and Skin Barrier Regulation? J Invest Dermatol, 2016. 136(3): p. 561-564.
Zuyderduyn, S., et al., IL-4 and IL-13 exposure during mucociliary differentiation of
bronchial epithelial cells increases antimicrobial activity and expression of antimicrobial
peptides. Respir Res, 2011. 12(1): p. 59.
Guttman-Yassky, E., et al., Dupilumab progressively improves systemic and cutaneous
abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol, 2019. 143(1): p. 155-172.
Harb, H. and T.A. Chatila, Mechanisms of Dupilumab. Clin Exp Allergy, 2020. 50(1): p. 5-14.
Wenzel, S., et al., Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J
Med, 2013. 368(26): p. 2455-66.
Moran, A. and I.D. Pavord, Anti-IL-4/IL-13 for the treatment of asthma: the story so far.
Expert Opin Biol Ther, 2020. 20(3): p. 283-294.
Jansen, F., et al., Dupilumab (Dupixent(®)) tends to be an effective therapy for uncontrolled
severe chronic rhinosinusitis with nasal polyps: real data of a single- centered, retrospective
single-arm longitudinal study from a university hospital in Germany. Eur Arch Otorhinolaryngol,
280(4): p. 1741-1755.
Peters, A.T., et al., Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis
with Nasal Polyps. J Allergy Clin Immunol Pract, 2021. 9(6): p. 2461-2471 e5.
Hellings, P.W., E. Verhoeven, and W.J. Fokkens, State-of-the-art overview on biological
treatment for CRSwNP. Rhinology, 2021. 59(2): p. 151-163.
Soler, Z., et al., ASSOCIATION BETWEEN SMELL LOSS, DISEASE BURDEN, AND DUPILUMAB EFFICACY IN
CHRONIC RHINOSINUSITIS WITH NASAL POLYPS. Annals of Allergy, Asthma &
Immunology, 2022. 129: p. S72.
Bachert, C., Hopkins, C., Han, J., Fokkens, W., Mannent, L, Symptom free days in patients
with severe chronic rhinosinusitis with nasal polyps treated with dupilumab. OURNAL OF ALLERGY AND
CLINICAL IMMUNOLOGY, 2022. 149(2): p. AB143–AB143.
Bachert, C., et al., Onset, Maintenance, and Durability of Response with Dupilumab in Chronic
Rhinosinusitis with Nasal Polyps. 2022. 1711.
Mullol, J., et al., Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal
Polyps. J Allergy Clin Immunol Pract, 2022. 10(4): p. 1086-1095 e5.
Mullol, J., et al., Efficacy and safety of dupilumab in patients with uncontrolled severe
chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two
randomized placebo-controlled phase 3 trials. Allergy, 2022. 77(4): p. 1231-1244.
Lee, S.E., et al., Dupilumab improves health related quality of life: Results from the phase
SINUS studies. Allergy, 2022. 77(7): p. 2211-2221.
Hopkins, C., et al., Efficacy of dupilumab in patients with a history of prior sinus surgery
for chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol, 2021. 11(7): p. 1087- 1101.
Bachert, C., et al., Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal
polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type
inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24
and SINUS-52 trials. Int Forum Allergy Rhinol, 2022. 12(9): p. 1191- 1195.
Fujieda, S., et al., The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal
Polyps in Japan. Laryngoscope, 2021. 131(6): p. E1770-E1777.
Laidlaw, T.M., et al., Dupilumab improves upper and lower airway disease control in chronic
rhinosinusitis with nasal polyps and asthma. Ann Allergy Asthma Immunol, 2021. 126(5): p.
-592.e1.
Bachert, C., et al., Efficacy and safety of dupilumab in patients with severe chronic
rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two
multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet,
394(10209): p. 1638-1650.
Bachert, C., et al., Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With
Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA, 2016. 315(5): p. 469-79.
Bachert, C., et al., DUPILUMAB IMPROVES CHRONIC RHINOSINUSITIS WITH NASAL POLYPS DISEASE
OUTCOMES IRRESPECTIVE OF TYPE 2 SIGNATURE DEFINITION. Annals of Allergy,
Asthma & Immunology, 2022. 129: p. S72-S73.
Kim, J. and R. Naclerio, Therapeutic Potential of Dupilumab in the Treatment of Chronic
Rhinosinusitis with Nasal Polyps: Evidence to Date. Ther Clin Risk Manag, 2020. 16: p. 31- 37.
Swisher, A.R., et al., Dupilumab Adverse Events in Nasal Polyp Treatment: Analysis of FDA
Adverse Event Reporting System. Laryngoscope, 2022. 132(12): p. 2307-2313.
Kilty, S.J. and A. Lasso, Canadian real-world study of access and clinical results using
dupilumab for chronic rhinosinusitis with polyps. J Otolaryngol Head Neck Surg, 2022. 51(1): p. 17.
De Corso, E., et al., Effectiveness of Dupilumab in the Treatment of Patients with Severe
Uncontrolled CRSwNP: A "Real-Life" Observational Study in the First Year of Treatment. J Clin Med,
11(10).
ศูนย์เฝ้าระวังความปลอดภัยด้านผลิตภัณฑ์สุขภาพ, สรุปรายงาน ADR/AE ประจ าปี (Spontaneous Report
Summary, SRS). 2023.
Brentwood TN, O.o.T.I.S.O., Mother To Baby | Fact Sheets. 2023.
Khamisy-Farah, R., et al., Safety profile of Dupilumab during pregnancy: a data mining and
disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting
database (VigiBase). Eur Rev Med Pharmacol Sci, 2021. 25(17): p. 5448-5451.
Shakuntulla, F. and S.E. Chiarella, Safety of Biologics for Atopic Diseases During Pregnancy.
J Allergy Clin Immunol Pract, 2022. 10(12): p. 3149-3155.
Sanofi, Post-authorization Safety Study in North America to Monitor Pregnancy and Infant
Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy. 2019.
Sanofi, An Observational Retrospective Cohort Study Being Conducted in Women With Atopic
Dermatitis (AD). 2019.
DUPIXENT® (dupilumab) injection package insert. 2017.
Grayson, J.W., et al., Contemporary Classification of Chronic Rhinosinusitis Beyond Polyps vs
No Polyps: A Review. JAMA Otolaryngol Head Neck Surg, 2020. 146(9): p. 831-838.
Sciascia, S., C. Ponticelli, and D. Roccatello, Pathogenesis-based new perspectives of
management of ANCA-associated vasculitis. Autoimmun Rev, 2022. 21(3): p. 103030.
Puéchal, X., Granulomatosis with polyangiitis (Wegener's). Joint Bone Spine, 2020. 87(6): p.
-578.
Bayrak Durmaz, M.S., Z. Çelebi Sözener, and S. Bavbek, Eosinophilic granulomatosis with
polyangitis: A new target for biologicals. Tuberk Toraks, 2022. 70(1): p. 93-101.
Caminati, M., et al., Biologics for eosinophilic granulomatosis with polyangiitis. Curr Opin
Allergy Clin Immunol, 2023. 23(1): p. 36-43.
Wechsler, M.E., et al., Mepolizumab or Placebo for Eosinophilic Granulomatosis with
Polyangiitis. N Engl J Med, 2017. 376(20): p. 1921-1932.
Canzian, A., et al., Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic
Granulomatosis With Polyangiitis: Data From a European Collaborative Study. Arthritis
Rheumatol, 2021. 73(3): p. 498-503.
Bettiol, A., et al., Sequential rituximab and mepolizumab in eosinophilic granulomatosis with
polyangiitis (EGPA): a European multicentre observational study. Ann Rheum Dis, 2022. 81(12): p.
-1772.
Bettiol, A., et al., Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A
European Multicenter Observational Study. Arthritis Rheumatol, 2022. 74(2): p. 295-306.
Chung, S.A., et al., 2021 American College of Rheumatology/Vasculitis Foundation Guideline
for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis
Rheumatol, 2021. 73(8): p. 1366-1383.
Koga, Y., et al., Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic
Granulomatosis With Polyangiitis. Front Pharmacol, 2022. 13: p. 865318.
Takenaka, K., et al., Decrease in MPO-ANCA after administration of benralizumab in
eosinophilic granulomatosis with polyangiitis. Allergol Int, 2019. 68(4): p. 539-540.
Nanzer, A.M., et al., Steroid-sparing effects of benralizumab in patients with eosinophilic
granulomatosis with polyangiitis. ERJ Open Res, 2020. 6(4).
Padoan, R., et al., Benralizumab as a glucocorticoid-sparing treatment option for severe
asthma in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract, 2020. 8(9):
p. 3225-3227.e2.
Coppola, A., K.R. Flores, and F. De Filippis, Rapid onset of effect of benralizumab on
respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis. Respir Med
Case Rep, 2020. 30: p. 101050.
Colantuono, S., et al., Early benralizumab for eosinophilic myocarditis in eosinophilic
granulomatosis with polyangiitis. Allergol Int, 2020. 69(3): p. 483-484.
Lee, Y. and M. Hojjati, Benralizumab as a Potential Adjunctive Therapy in Eosinophilic
Granulomatosis With Polyangiitis. J Clin Rheumatol, 2021. 27(8s): p. S401-s402.
Carrillo-Martin, I., et al., An alternative approach against eosinophils for the treatment of
eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract, 2020. 8(6): p.
-2080.
Chica-Guzman, M.V., et al., Eosinophilic granulomatosis with polyangiitis successfully
treated with benralizumab. Ann Allergy Asthma Immunol, 2020. 125(2): p. 228-230.
Martinez-Rivera, C., et al., Rapid effect of benralizumab in exacerbation of severe
eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis. BMC Pulm Med,
21(1): p. 35.
Guntur, V.P., et al., Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic
Granulomatosis with Polyangiitis. J Allergy Clin Immunol Pract, 2021. 9(3): p. 1186-1193.e1.
Hinds, D.M., et al., Pulmonary eosinophilic vasculitis with granulomas and benralizumab in
children. Pediatr Pulmonol, 2021. 56(6): p. 1789-1792.
Bormioli, S., et al., Benralizumab: Resolution of Eosinophilic Pulmonary Vasculitis in a
Patient With EGPA. J Investig Allergol Clin Immunol, 2021. 31(6): p. 519-521.
Kolios, A.G.A., et al., Benralizumab in eosinophilic granulomatosis with polyangiitis
complicated by Staphylococcus aureus sepsis. Clin Immunol, 2021. 222: p. 108574.
Menzella, F., et al., Efficacy and steroid-sparing effect of benralizumab: has it an
advantage over its competitors? Drugs Context, 2019. 8: p. 212580.
Miyata, Y., et al., Efficacy of Benralizumab and Clinical Course of IgG4 in Eosinophilic
Granulomatosis With Polyangiitis. J Investig Allergol Clin Immunol, 2021. 31(4): p. 346-348.
AstraZeneca, A study to evaluate if benralizumab compared to mepolizumab may be beneficial in
the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) (MANDARA). 2023.
Southern, K.W., et al., Corrector therapies (with or without potentiators) for people with
cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst
Rev, 2020. 12(12): p. Cd010966.
Schwitzguébel, A.J., et al., Immunoglobulin deficiency in patients with chronic
rhinosinusitis: Systematic review of the literature and meta-analysis. J Allergy Clin Immunol,
136(6): p. 1523-1531.
Roberts, D.M., et al., Rituximab-associated hypogammaglobulinemia: incidence, predictors and
outcomes in patients with multi-system autoimmune disease. J Autoimmun, 2015. 57: p. 60-5.
Iacovou, E., et al., Diagnosis and treatment of HIV-associated manifestations in
otolaryngology. Infect Dis Rep, 2012. 4(1): p. e9.
Sanjar, F.A., B.E. Queiroz, and I.D. Miziara, Otolaryngologic manifestations in HIV disease--
clinical aspects and treatment. Braz J Otorhinolaryngol, 2011. 77(3): p. 391-400.
Chiarella, S.E. and L.C. Grammer, Immune deficiency in chronic rhinosinusitis: screening and
treatment. Expert Rev Clin Immunol, 2017. 13(2): p. 117-123.
Gill, P.K. and S.D. Betschel, Timing of infections in patients with primary
immunodeficiencies treated with intravenous immunoglobulin (IVIg). Allergy Asthma Clin Immunol,
14: p. 35.
Khalid, A.N., J.C. Mace, and T.L. Smith, Outcomes of sinus surgery in ambulatory patients
with immune dysfunction. Am J Rhinol Allergy, 2010. 24(3): p. 230-3.
Dao, A.M., et al., Management of non-invasive rhinosinusitis in the immunosuppressed
patient population. Laryngoscope, 2015. 125(8): p. 1767-71.